Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369] Draft guidance Technology appraisal guidance 2 April ...

ASSESS-DHT is a European project that aims to increase the adoption of trustworthy and effective digital health technologies (DHTs) across Europe. The project will address the challenges with ...

Our highly specialised technologies (HST) programme is designed specifically to evaluate technologies for ultra-rare, debilitating conditions. It helps encourage research and innovation in areas where ...

The treatment, called relugolix–estradiol–norethisterone (also known as relugolix combination therapy or Ryeqo), works by blocking specific hormones that contribute to endometriosis, while also ...

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

NICE guidance published today recommends leniolisib (also called Joenja and made by Pharming) for treating activated phosphoinositide 3-kinase delta syndrome (APDS) in people 12 years and over.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

We've published a draft quality standard calling for yearly BMI and waist-to-height measurements to help prevent weight-related complications.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

To declare any new board interests and executive team interests, and consider any conflicts of interest specific to the meeting. Minutes of the last board meeting (Word) To approve the minutes of the ...